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1. Introduction 
Ultrasound imaging has been utilized for the non-invasive and real-time observation of 
pathophysiological conditions in clinical settings. To enhance blood flow signals, 
microbubbles that are quite different in acoustic impedance from blood have been utilized 
as the contrast agent for ultrasound imaging. Unfortunately, the initial performance of 
intravenous contrast-enhanced ultrasound imaging was hampered by the pulmonary 
circulation due to the size of the microbubbles. Additionally, the detection of microbubbles 
was not easy because of the weak signals derived from the bubbles. However, recent 
improvements in the bubble physics and ultrasound imaging technologies have enabled 
non-invasive assessment of organ perfusion by intravenous administration of microbubbles 
(Chahal & Senior, 2010; Porter & Xie, 2010; Wilson & Burns, 2010). Of note, the fate of 
intravenously administrated microbubbles is similar to that of red blood cells (Keller et al., 
1989; Jayaweera et al., 1994). Many contrast agents for contrast-enhanced ultrasound 
imaging are now clinically available all over the world (Table 1). 
On the other hand, ultrasound molecular imaging, which visualizes molecular dynamics in 
situ by detecting the signals derived from retained microbubbles in the target regions, has 
been recently developed. As microbubbles are the intravascular blood flow tracer, 
ultrasound molecular imaging predominantly targets activated leukocytes and molecules 
expressed on endothelial cells. Many papers have been published regarding the diagnostic 
utility of ultrasound molecular imaging for the detection of inflammation, atherosclerosis 
and tumor angiogenesis (Villanueva & Wagner, 2008; Leong-Poi, 2009; Lindner, 2009; 
Chadderdon & Kaul, 2010; Deshpande et al., 2010). 
The utility of molecular imaging has been demonstrated using several modalities, including 
positron emission tomography (PET), magnetic resonance imaging (MRI) and near-infrared 
fluorescence (NIRF) (Jaffer & Weissleder, 2005). Although PET and MRI provide accurate 
diagnostic information, the versatility of these two modalities is limited. On the other hand, 
ultrasound examination is cost effective and is able to be performed at the bedside. 
Therefore, the adaptation of ultrasound molecular imaging for clinical settings is desired. 
For the clinical translation of ultrasound molecular imaging, however, some bottlenecks 
need to be overcome at the same time, including the development of clinically translatable 
targeted bubbles and the improvement of ultrasound imaging techniques. This chapter 
summarizes the recent advances in the preparation of targeted bubbles and ultrasound 
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imaging technologies for realizing the clinical translation of ultrasound molecular imaging 
in the near future. 
 
 Core gas Shell composition Mean diameter 
Levovist 
Bayer Yakuhin, Ltd. 
Osaka, Japan 
Air Palmitic acid 2.0-3.0 μm 
Optison 
GE Healthcare 
Buckinghamshire, UK 
C3F8 Human serum albumin 3.0—4.5 μm 
Definity 
Lantheus Medical Imaging, Inc. 
N. Billerica, MA 
C3F8 Phospholipid 1.1-3.3 μm 
Sonovue 
Bracco Imaging SpA 
Milan, Italy 
SF6 Phospholipid 2.5 μm 
Sonazoid 
Daiichi-Sankyo Co., Ltd. 
Tokyo, Japan 
C4F10 
Hydrogenated egg 
phosphatidylserine 
2.0-3.0 μm 
Table 1. Commercially available ultrasound contrast agents 
2. Recent progress in development of targeted bubbles 
In the previously reported animal studies with ultrasound molecular imaging, various 
intravital molecules have served as target molecules (Chadderdon & Kaul, 2010; Hwang et 
al., 2010). In ultrasound molecular imaging, the methodology for accumulating bubbles at a 
specific target is a principal issue. Until now, two types of bubbles have been developed to 
achieve this purpose, including non-targeted and targeted bubbles (Dayton & Rychak, 2007; 
Deshpande et al., 2010) (Table 2). 
 
 Method to modify bubbles Application 
Non-targeted bubbles 
Incorporate phospholipids/lipids 
into bubble shell by sonication 
Inflammation imaging, 
Kupffer imaging 
Targeted bubbles 
Attach ligands onto bubble surface 
via covalent/non-covalent coupling 
Overall 
Table 2. Two types of bubbles for ultrasound molecular imaging 
Non-targeted bubbles contain phosphatidylserine (PS) or other lipids in their shell 
components, and have been utilized as the contrast agent for inflammation and Kupffer cell 
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imaging (Lindner et al., 2000; Christiansen et al., 2002; Watanabe et al., 2007; Yanagisawa et 
al., 2007). On the other hand, targeted bubbles bear antibodies or peptides on the surface of 
the shell via chemical conjugation, including covalent or non-covalent coupling methods 
(Hernot & Klibanov, 2008; Deshpande et al., 2010). Several kinds of potential covalent 
coupling reaction have been considered for the attachment of ligands onto the surface of 
bubbles (Klibanov, 2005; Kiessling et al., 2009) (Table 3). However, the major method for 
ligand attachment in recent ultrasound molecular imaging studies was non-covalent avidin-
biotin complex formation because of its versatility. 
 
 Primary coupling reaction 
Covalent coupling 
Carboxylic Acid (-COOH) / Amine (-NH2) 
Maleimide / Thiol (-SH) 
Aldehyde (-CHO) / Amine (-NH2)  etc. 
Non-covalent coupling Biotin / Avidin or Streptavidin 
Table 3. Coupling strategies for attachment of ligands onto bubble shell 
It is well known that the binding between biotin and streptavidin exhibits extremely high 
affinity (dissociation constant ~10-15); however, at the same time, streptavidin is a major 
barrier for clinical translation of targeted bubbles. Because of the immunogenicity of 
streptavidin, repeated injection of streptavidin-containing bubbles is difficult in humans 
(Marshall et al., 1996; Carter, 2001). Therefore, the development of targeted bubbles that do 
not contain streptavidin is necessary for the clinical translation of ultrasound molecular 
imaging. 
2.1 Commercially available targeted bubbles for basic research 
Because of its difficulty, the preparation of targeted bubbles has been a principal issue in 
ultrasound molecular imaging. Fortunately, several targeted bubbles only for use in basic 
research have been developed recently; MicroMarker® (VisualSonics Inc., Toronto, Canada) 
and Targestar™/Visistar™ (Targeson Inc., San Diego, CA, USA). Because of their versatility, 
these bubbles have been well utilized in in vivo studies (Rychak et al., 2007; Willmann et al., 
2008a, 2008b, 2010; Barreiro et al., 2009). However, the clinical application of these bubbles is 
difficult in the present condition because of the use of streptavidin as a mediator between 
bubbles and ligands. 
2.2 Chemical modification to improve targetability of bubbles 
For ultrasound molecular imaging, improvement of the targetability of ligand-bearing 
bubbles to the disease-related intravital molecule is a principal issue. To this end, several 
chemical modifications have been recently applied to targeted bubbles (Klibanov, 2009; 
Gessner & Dayton, 2010). Firstly, Klibanov et al. conjugated clustered polymeric forms of 
ligands onto the surface of the bubble shell to increase the surface density of ligands 
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(Klibanov et al., 2006b). Secondly, targeted bubbles for two intravital molecules have been 
developed by simultaneous conjugation of two kinds of ligands onto the bubble shell 
(Weller et al., 2005; Willmann et al., 2008b; Ferrante et al., 2009). However, dense ligands, 
especially antibodies on the bubble surface would increase the risk of non-specific binding 
and immunogenic responses at the same time. To overcome this issue, Borden et al. 
developed “stealth bubbles” those ligands were buried in a forest of long polyethylene 
glycol (PEG)-brushes (Borden et al., 2008). In this stealth bubble, a radiation force was 
required to induce emergence and activation of the buried ligands. Therefore, the utilization 
of buried ligands might enable the development of targeted bubbles with both low non-
specific binding and low immunogenic response. 
2.3 Streptavidin-free targeted ultrasound contrast agents 
Recently, several approaches for the preparation of targeted bubbles without streptavidin 
have been demonstrated. Anderson et al. utilized covalent maleimide-thiol coupling for 
conjugating the targeting ligands onto the bubble shell (Anderson et al., 2010). As well as 
avidin-biotin binding, this covalent coupling approach would be applicable to a wide 
variety of ligands in the near future. Meanwhile, novel vascular endothelial growth factor 2 
(VEGFR2)-specific bubbles; BR55, which contains a lipopeptide construct in the bubble shell, 
was recently developed (Pysz et al., 2010; Pochon et al., 2010; Tardy et al., 2010). Since BR55 
contains neither antibodies nor biotin/streptavidin complex, the clinical translation of 
targeted bubbles for angiogenesis without an immunogenic response might be feasible by 
using BR55. 
2.4 Preparation of targeted bubbles based on clinically available bubbles 
To achieve easy translation of ultrasound molecular imaging in clinical settings, we 
considered that the easiest approach would be the preparation of targeted bubbles based on 
a clinically available ultrasound contrast agent. However, there have been no reports 
regarding the preparation of targeted bubbles based on a clinically available contrast agent. 
Sonazoid, a clinically available ultrasound contrast agent in Japan, consists of 
perfluorobutane gas microbubbles stabilized by a membrane of hydrogenated egg PS 
(Sontum, 2008). Generally, PS is well known as an important molecule in the cellular 
apoptotic process, especially in the clearance of apoptotic cells (Wu et al., 2006; Nagata et al., 
2010). Under normal physiological conditions, PS is sequestered from the cell surface by 
phospholipid translocators, known as flippases. However, this process is interrupted during 
apoptosis and PS translocates to the cell surface. This translocation of PS triggers the 
recognition and removal of apoptotic cells by phagocytes. In the field of apoptotic 
research, annexin V has been well utilized for detecting PS-expressing apoptotic cells 
(Vermes et al., 1995). Recently, the clinical availability of annexin V for the detection of 
apoptosis or plaque instability was demonstrated (Hofstra et al., 2000; Narula et al., 2001; 
Kietselaer et al., 2004). 
In ultrasound molecular imaging, PS-containing bubbles have been utilized as targeted 
bubbles for activated leukocytes (Lindner et al., 2000; Christiansen et al., 2002). Interestingly, 
PS-containing bubbles were labeled with annexin V as well as apoptotic cells (Lindner et al., 
2000). Based on this result, we hypothesized that preparation of antibody-carrying bubbles 
based on Sonazoid could be feasible by detecting PS in Sonazoid with annexin V and 
utilizing avidin-biotin complex formation (Figure 1). 
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Fig. 1. Theoretical schema of IgG antibody-carrying bubbles based on Sonazoid through use 
of annexin V and avidin-biotin complex formation. 
As annexin V is a well-known protein that detects PS in a Ca2+-dependent manner, we firstly 
examined the effect of Ca2+ addition on Sonazoid bubbles. By adding a higher concentration 
of CaCl2, obvious and significant aggregation of bubbles was observed (Figure 2A). The size 
distribution histogram was markedly smaller after the addition of 0.25 mmol/L CaCl2 than 
that of naked Sonazoid bubbles (Figure 2B). Additionally, the bubble concentration was 
markedly reduced after the addition of 0.25 mmol/L CaCl2 (naked Sonazoid: 5.3x108 
bubbles/mL vs. 0.25 mmol/L CaCl2: 7.0x107 bubbles/mL). This phenomenon was 
considered to result from neutralization of the surface charge of Sonazoid bubbles (Otani & 
Yamahara, 2011). However, bubble number was not decreased after the addition of 0.05 
mmol/L CaCl2 (5.8x108 bubbles/mL) (Figure 2B). Therefore, the following experiments were 
performed in the presence of 0.05 mmol/L CaCl2, which did not induce obvious aggregation 
of Sonazoid bubbles. 
Secondly, the attachment of annexin V to the PS in Sonazoid bubbles was examined using 
fluorescein isothiocianate (FITC)-conjugated annexin V. The fluorescent signal was 
determined by FACSCalibur (BD Bioscience, San Jose, CA, USA). Even in the condition with 
low Ca2+, FITC-positive bubbles were observed after the conjugation of Sonazoid bubbles 
with FITC-annexin V (Figure 3). In contrast, the fluorescent signal derived from bubbles 
after conjugation in the absence of Ca2+ was significantly reduced. These results imply that 
the PS in Sonazoid could be detected by using annexin V even in the condition of 0.05 
mmol/L CaCl2 (Otani & Yamahara, 2011). 
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Fig. 2. Changes of Sonazoid bubbles after addition of CaCl2. A) At 30 minutes after addition 
of CaCl2, obvious bubble aggregation was observed when the concentration of CaCl2 was 
0.25 mmol/L or higher. B) The size distribution of Sonazoid bubbles was markedly altered 
at 45 minutes after 0.25 mmol/L CaCl2 addition. (Reproduced from Otani et al. with 
permission) 
Thirdly, we examined whether streptavidin could detect biotinylated-Sonazoid bubbles 
with annexin V. Sonazoid bubbles were conjugated with biotinylated-annexin V followed by 
R-phycoerythrin (PE)-conjugated streptavidin. A strong PE signal was detected from 
Sonazoid bubbles in the presence of biotinylated-annexin V (Figure 4). However, the PE 
signal was obviously weaker in the absence of biotinylated-annexin V. These results imply 
that streptavidn could attach to the surface of Sonazoid via avidin-biotin binding. 
Finally, we examined whether the attachment of IgG antibodies onto the surface of Sonazoid 
bubbles is feasible via annexin V and avidin-biotin complex formation. Sonazoid bubbles 
were conjugated with biotinylated-annexin V followed by streptavidin and biotinylated-
Alexa488-IgG. As shown in Figure 5A, Alexa488-positive bubbles were confirmed by FACS 
analysis (Otani & Yamahara, 2011). However, the suspension of targeted-Sonazoid bubbles 
was obviously thinner than that of naked Sonazoid bubbles (Figure 5B). 
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Fig. 3. Attachment of annexin V to PS on surface of Sonazoid bubble. In the presence of 
CaCl2, FITC-positive bubbles were detected after the conjugation of Sonazoid bubbles with 
FITC-annexin V. In contrast, the FITC signal derived from Sonazoid bubbles was markedly 
reduced in the absence of CaCl2. (Reproduced from Otani et al. with permission) 
 
 
Fig. 4. Attachment of streptavidin to surface of Sonazoid bubble via avidin-biotin binding. 
PE-positive bubbles were detected after conjugation of Sonazoid bubbles with biotinylated-
annexin V followed by PE-conjugated streptavidin. However, the PE signal was markedly 
reduced in the absence of biotinylated-annexin V. (Reproduced from Otani et al. with 
permission) 
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Fig. 5. IgG-carrying bubbles based on Sonazoid. A) Alexa488-positive Sonazoid bubbles 
were confirmed after conjugation with biotinylated-annexin V followed by streptavidin and 
biotinylated-Alexa488-IgG. B) The concentration of targeted bubbles based on Sonazoid was 
obviously lower than that of naked Sonazoid bubbles. (Reproduced from Otani et al. with 
permission) 
Although our preliminary results demonstrated the feasibility of preparation of targeted 
bubbles based on clinically available microbubbles Sonazoid, the translation of targeted 
Sonazoid bubbles to in vivo settings would be difficult in the present circumstances because 
of the decrease of bubble number and the use of streptavidin. However, our results imply 
that PS in Sonazoid bubbles has the potential to be a mediator of targeted bubbles based on 
Sonazoid. 
2.5 Improvement of targeted sonazoid by using lactadherin 
PS is well known as an important molecule for the clearance of apoptotic cells, and several 
kinds of proteins that bind with PS have been discovered (Wu et al., 2006; Nagata et al., 
2010). Milk fat globule epithelial growth factor 8 (MFG-E8)/lactadherin is a glycoprotein 
which was originally identified as a component of milk fat globules (Stubbs et al., 1990). 
Lactadherin contains a PS-binding C-domain and an RGD (arginine-glycine-aspartate)-motif 
present in the epidermal growth factor domain, which binds to integrins ┙v┚3 and ┙v┚5 
(Andersen et al., 2000; Hanayama et al., 2002; Yamaguchi et al., 2008). It is well known that 
the recognition of PS by lactadherin is Ca2+-independent (Shi et al., 2003; Dasgupta et al., 
2006). Therefore, we examined whether PS in Sonazoid could be detected using PE-
conjugated lactadherin instead of annexin V (Figure 6A). By conjugating Sonazoid bubbles 
with PE-labeled lactadherin, PE-positive bubbles were detected by FACS analysis (Figure 
6B, unpublished data). 
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Fig. 6. Detection of PS in Sonazoid using lactadherin. A) Schema of expected binding 
between Sonazoid bubbles and PE-conjugated lactadherin. B) After conjugation with PE-
lactadherin, the presence of PE-positive Sonazoid bubbles was confirmed. 
Because of the unnecessity of Ca2+ addition in the case of lactadherin, no obvious 
aggregation or decrease in number of bubbles was observed during the preparation of 
lactadherin-bearing bubbles (data not shown). Although the binding between Sonazoid 
bubbles and annexin V was fragile, robust binding with PS in Sonazoid was achieved using 
lactadherin (Figure 7). These results imply that lactadherin is superior to annexin V in 
regard to the detection of PS in Sonazoid bubbles. As lactadherin has a RGD motif in its 
epidermal growth factor domain, lactadherin-bearing Sonazoid bubbles might have the 
potential to attach to integrin ┙v┚3-expressing cells. Furthermore, lactadherin-bearing 
Sonazoid bubbles might be a novel targeted bubble for angiogenesis, because the integrin 
┙v┚3 is well known to play a key role in angiogenesis (Friedlander et al., 1995). Therefore, 
further study to examine the potential of lactadherin-bearing Sonazoid bubbles both in vitro 
and in vivo would be of benefit. 
Although the feasibility of preparation of targeted bubbles based on a clinically available 
ultrasound contrast agent was demonstrated in our present study, there are some concerns 
with lactadherin-bearing Sonazoid bubbles at the present time. The most important issue is 
the direct conjugation of lactadherin onto the bubble shell. This might influence: 1) the 
efficiency of attachment to the target molecule (integrin ┙v┚3) both in vitro and in vivo 
studies, and 2) the surface density of ligands. The majority of recent targeted bubbles 
contain long PEG spacer arms on the bubble surface to project ligands away from the 
surface of the bubble shell (Klibanov, 2006a; Lindner, 2010). This projection of ligands 
resulted in improvement of flexibility and targetability of bubbles. Furthermore, the surface 
density of ligands would be lower in the case of direct conjugation of ligands to the bubble 
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shell. In these regards, the efficiency of attachment of lactadherin-bearing Sonazoid bubbles 
to integrin ┙v┚3-expressing cells might be low. This concern should be clarified by further 
study. 
 
 
Fig. 7. Stability of annexin V- and lactadherin-bearing Sonazoid bubbles. Compared to 
annexin V-bearing Sonazoid bubbles, lactadherin-conjugated bubbles were more resistant to 
violent shaking. (Reproduced from Otani et al. with permission) 
3. Improvement of ultrasound technology 
In conjunction with the development of targeted bubbles, improvement of ultrasound 
technology is also an essential issue in ultrasound molecular imaging. Unlike conventional 
contrast-enhanced ultrasound imaging, the number of retained bubbles to the target region 
is quite small. Therefore, a more sensitive ultrasound detection technique would be required 
for the clinical translation of ultrasound molecular imaging. Additionally, a bubble-specific 
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imaging method that suppresses signals from surrounding tissues, to emphasize the 
ultrasound signals derived from bubbles, would be a help for accurate observation of 
molecular dynamics. 
3.1 Evolution of ultrasound detection techniques 
Contrast-enhanced ultrasound imaging visualizes the signals derived from microbubbles. 
Under high mechanical index (MI) ultrasound exposure, bubbles exhibit unique scattering 
behavior. By utilizing this characteristic, harmonic imaging, especially second harmonic 
imaging, has been developed at an early stage of contrast-enhanced ultrasound imaging 
(Porter et al., 1996). In addition, the Doppler technique has been applied for sensitive 
detection of bubbles (harmonic power Doppler imaging). Until now, several harmonic 
imaging techniques including subharmonic, 1.5 harmonic and ultraharmonic imaging have 
been developed (Table 4). However, high MI ultrasound exposure resulted in the 
destruction of bubbles - the source of acoustic signals. Therefore, intermittent exposure is 
inevitable for acquiring contrast-enhanced images in high MI imaging. As a result, real-time 
observation of contrast enhancement has not been achieved in high MI imaging. To 
overcome this issue, real-time imaging which utilizes low power ultrasound has been 
developed in conjunction with high MI imaging techniques. Until now, several techniques 
that detect the bubble signal efficiently with multiple ultrasound pulses have been 
developed, including pulse inversion, power pulse inversion, power modulation, coherent 
contrast imaging and cadence pulse sequencing (Table 4). 
 
 Imaging mode References 
High MI imaging techniques 
(for intermittent observation) 
Subharmonic imaging Forsberg et al., 2000 
1.5 harmonic imaging Toshida et al., 2005 
Ultraharmonic imaging Kuersten et al., 2001 
Harmonic power Doppler Heinle et al., 2000 
Low MI imaging techniques 
(for real-time observation) 
Pulse inversion Burns et al., 2000 
Power pulse inversion Tiemann et al., 1999 
Power modulation Caiani et al., 2005 
Coherent contrast imaging Otani et al., 2004 
Cadence pulse sequencing Phillips, 2001 
Table 4. Imaging technologies for contrast-enhanced ultrasound imaging 
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Compared to conventional contrast-enhanced ultrasound imaging, the number of retained 
or attached bubbles to the target region in ultrasound molecular imaging is quite small. 
Additionally, the sensitivity for bubble detection in high MI imaging is higher than that in 
low MI real-time imaging. Therefore, early examination of ultrasound molecular imaging 
had been performed using high MI, intermittent imaging (Lindner et al., 2001; Leong-Poi et 
al., 2003). However, high MI imaging interferes with the continuous imaging of molecular 
dynamics, due to the destruction of retained or attached bubbles. Recently, low MI, real-
time imaging has been applied in ultrasound molecular imaging (Kaufmann et al., 2007; 
Stieger et al., 2008). Although the acoustic signal derived from targeted bubbles in low MI 
real-time imaging was weaker than that in high MI imaging, real-time ultrasound molecular 
imaging would enable temporal and spatial recognition of molecular dynamics (Kaufmann 
et al., 2010). Additionally, Klibanov et al. reported the feasibility of individual bubble 
detection using low MI ultrasound imaging (Klibanov et al., 2004). This result implied that 
the sensitivity of low MI ultrasound techniques would be sufficient for application to 
ultrasound molecular imaging. 
3.2 Specialized ultrasound machine for small animal research 
In previous small animal studies on ultrasound perfusion and molecular imaging, the 
detection of bubbles has been performed using clinically available ultrasound imaging 
systems (Weller et al., 2003; Otani et al., 2008). Recently, high resolution ultrasound imaging 
systems specialized for small animal experiments have been developed (Vevo770 and 
Vevo2100; VisualSonics Inc., Toronto, Canada). Several recent basic research studies on 
ultrasound molecular imaging have utilized these machines (Rychak et al., 2007; Willmann 
et al., 2008a, 2008b, 2010). Because of the usage of too high frequency ultrasound (center 
frequency; ~ 55 MHz), this machine would not be suitable for clinical use. However, the 
accumulated results from genetically-modified animal studies using these instruments will 
be of much help for the clinical translation of ultrasound molecular imaging. 
4. Conclusion and future direction 
Contrast-enhanced ultrasound imaging has been applied in clinical settings, and its usability 
has also been demonstrated all over the world. On the other hand, the utility of ultrasound 
molecular imaging has been proved by many animal studies. Therefore, the development of 
clinically translatable targeted bubbles has potential for spreading ultrasound molecular 
imaging into clinical settings rapidly. In parallel with perfusion or molecular imaging, the 
potential of microbubbles as a carrier for drug or gene delivery into cells has been 
demonstrated recently in both in vitro and in vivo studies (Liu et al., 2006; Otani et al., 2009; 
Tinkov et al., 2009). The combination of these features might lead to the localized delivery of 
drugs or genes into target cells in vivo. Although further study is required, progress in 
targeted bubbles physics and ultrasound imaging technologies might realize the clinical 
application of ultrasound molecular imaging and the development of non-invasive localized 
drug/gene delivery systems in the near future. 
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